Canakinumab, a human neutralizing monoclonal antibody to IL-1β, has been approved for the treatment of systemic inflammatory diseases such as cryopyrin-associated periodic syndrome (CAPS), systemic-onset juvenile idiopathic arthritis, and refractory gout (26). The gene discussed is IL1B; the disease is cryopyrin-associated periodic syndrome.